This Medudy course is a video tutorial for physicians on the topic “Advances in the Treatment of Urothelial Carcinoma: The Bispecific ADC Iza-bren for MIUC.”
In this video, Prof. Günter Niegisch, MD, a senior physician at the Department of Urology at the University Hospital of Düsseldorf and principal investigator of the Izabright-Bladder01 study, will present the antibody-drug conjugate Iza-bren in the context of advanced urothelial carcinoma.
He will discuss both the dual mechanism of action of the bispecific antibody-drug conjugate targeting EGFR and HER3 and the potential role of Iza-bren in the treatment of advanced urothelial carcinoma, which is currently being investigated in the IZABRIGHT-Bladder01 study.
Note: All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactics of the videos. The people on whom the avatars are based have explicitly consented to their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy medical team.
The course was created with the kind support of BMS.
At the end of this training you will know:
- the molecular structure and mechanism of action of Iza-bren
- The potential role of Iza-bren in the treatment of advanced urothelial carcinoma
- The IZABRIGHT Bladder01 study design
